Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin.
Currently controversy exists about the immunogenicity of seasonal trivalent influenza vaccine in certain populations, especially the elderly. STF2.4×M2e (VAX102) is a recombinant fusion protein that links four copies of the ectodomain of influenza virus matrix protein 2 (M2e) antigen to Salmonella t...
Main Authors: | H Keipp Talbot, Michael T Rock, Casey Johnson, Lynda Tussey, Uma Kavita, Anita Shanker, Alan R Shaw, David N Taylor |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-12-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3010987?pdf=render |
Similar Items
-
The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines
by: S. M. Kharit, et al.
Published: (2017-06-01) -
Immunogenicity and safety of a trivalent inactivated influenza vaccine
by: Eddy Fadlyana, et al.
Published: (2011-02-01) -
Immunopotentiating and Delivery Systems for HCV Vaccines
by: Alexander K. Andrianov, et al.
Published: (2021-05-01) -
Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season
by: Stephen I. Pelton, et al.
Published: (2020-08-01) -
Adverse Reactions of Trivalent Influenza Vaccine in HIV-Infected Individuals
by: Mahboube Hajiabdolbaghi, et al.
Published: (2010-04-01)